Follow our progress.

Milestones in our journey to reinvent genetic testing.

Press Releases

Invitae reports over 150% volume and over 170% revenue growth for 2017

Invitae reports over 150% volume and over 170% revenue growth for 2017

February 12, 2018

Annual test volume exceeds high end of guidance

Robust test volume and revenue growth expected to continue in 2018 and beyond

Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced financial and operating results for the fourth quarter and full year ended December 31, 2017.

“Over the past year, we have made significant strategic investments that we believe uniquely position our ...

Read more


Invitae to participate in two upcoming investor conferences, including the 2018 BIO CEO & Investor Conference and Leerink Partners 7th Annual Global Healthcare Conference

Invitae to participate in two upcoming investor conferences, including the 2018 BIO CEO & Investor Conference and Leerink Partners 7th Annual Global Healthcare Conference

January 31, 2018

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George, chief executive officer of Invitae, will participate in two upcoming investor conferences being held in New York City.

Sean George will present at the 2018 BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 10:00 a.m. Eastern / 7:00 a.m. Pacific. Additionally, Sean George will participate in a fireside chat at the Leerink Partners 7th Annual Global Healthcare ...

Read more


Invitae to announce fourth quarter and year-end 2017 financial results on February 12, 2018

Invitae to announce fourth quarter and year-end 2017 financial results on February 12, 2018

January 29, 2018

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it will report its fourth quarter and year-end 2017 financial results on Monday, February 12, 2018 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent developments.

The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and ...

Read more


Invitae more than doubles annual volume, exceeds full-year 2017 guidance, and projects momentum to continue in 2018

Invitae more than doubles annual volume, exceeds full-year 2017 guidance, and projects momentum to continue in 2018

January 08, 2018

127% increase in annual test volume exceeds high end of projected range

136% increase in full-year 2017 revenue in line with guidance

Anticipates continued, robust test volume and revenue growth in 2018 on strength of newly expanded business

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, announced preliminary full-year 2017 results that demonstrate continued strong momentum, with volume and revenue more than doubling compared to 2016 results. Preliminary financial results for 2017 include:

  • 127% year-over-year growth ...

Read more


Invitae to present at the 36th Annual J.P. Morgan Healthcare Conference

Invitae to present at the 36th Annual J.P. Morgan Healthcare Conference

December 20, 2017

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George, chief executive officer of Invitae, will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 2:00 p.m. Pacific at The Westin St. Francis in San Francisco.

The live webcast of the presentation may be accessed by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast will ...

Read more


Multigene Genetic Testing Improves Identification and Management of Hereditary Cancer Risk for Breast Cancer Patients and Their Families

Multigene Genetic Testing Improves Identification and Management of Hereditary Cancer Risk for Breast Cancer Patients and Their Families

December 05, 2017

Invitae to present findings at 2017 San Antonio Breast Cancer Symposium

Research presented today by Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, shows how clinicians are using genetic testing beyond BRCA1 and BRCA2 to guide treatment and screening decisions for hereditary breast and ovarian cancer (HBOC) patients and their families. The data are being presented at the 2017 San Antonio Breast Cancer Symposium.

Earlier research from Invitae published in the October issue of Annals of ...

Read more


Invitae Completes Acquisition of CombiMatrix, Becoming a Leader in Family and Reproductive Health Genetic Information Services

Invitae Completes Acquisition of CombiMatrix, Becoming a Leader in Family and Reproductive Health Genetic Information Services

November 15, 2017

Complements recent acquisition of Good Start Genetics to establish comprehensive service for IVF clinics, ob/gyns

Entry into family health genetics creates integrated platform to support use of genetics in mainstream medical care

Results of warrant exchange offer announced

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced it has completed its acquisition of CombiMatrix, which specializes in providing genetic information for prenatal diagnosis, miscarriage analysis and diagnosis of pediatric developmental disorders, establishing Invitae as ...

Read more


Invitae Corporation Issues Reminder Regarding Exchange Offer for CombiMatrix Corporation Series F Warrants

Invitae Corporation Issues Reminder Regarding Exchange Offer for CombiMatrix Corporation Series F Warrants

November 08, 2017

Exchange Offer to Expire One Minute After 11:59 p.m., New York City Time, on November 13, 2017, Unless Extended

Invitae Corporation (NYSE: NVTA) one of the fastest growing genetic information companies, today issued a reminder to CombiMatrix Corporation Series F warrant holders regarding the previously announced offer to exchange (the “Exchange Offer”) each outstanding Series F warrant (CUSIP No. 20009T147) (the “CombiMatrix Series F warrants”) to acquire one share of common stock of CombiMatrix Corporation (“CombiMatrix”) for 0 ...

Read more


Invitae Reports Double-Digit Sequential Volume and Revenue Growth  in Third Quarter 2017

Invitae Reports Double-Digit Sequential Volume and Revenue Growth in Third Quarter 2017

November 06, 2017

Momentum in base business complemented by strategic expansion into family health genetics

Hosting conference call today at 4:30 pm ET / 1:30 pm PT

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced financial and operating results for the quarter ended September 30, 2017, including continued business momentum, double-digit sequential volume and revenue growth, and a strengthened financial position.

Third Quarter 2017 Operational Highlights

  • Strategic expansion into reproductive health creates comprehensive platform offering genetic ...

Read more


Invitae Presents Validation of a Novel NGS-based Preimplantation Genetic Screening Technology to Identify the Most Frequent Chromosomal Causes of Miscarriage

Invitae Presents Validation of a Novel NGS-based Preimplantation Genetic Screening Technology to Identify the Most Frequent Chromosomal Causes of Miscarriage

October 30, 2017

Research showing re-biopsy may help preserve healthy embryos also presented at the American Society for Reproductive Medicine 2017 Scientific Congress & Expo

Invitae (NYSE: NVTA), one of the fastest growing genetic information companies, is presenting validation data for a novel, NGS-based preimplantation genetic screening (PGS) technology that accurately identifies certain chromosomal abnormalities potentially missed on other PGS platforms. In addition, company researchers are sharing data suggesting that if initial PGS testing yields no results, a second biopsy may provide actionable ...

Read more